Mandate

Vinge advises Zengun Group AB

July 04, 2019 M&A

Vinge has advised Zengun Group AB (publ) in connection with the acquisition of the Zengun Group and in conjunction with a bond issue.

Vinge has advised Zengun Group AB (publ), in connection with the acquisition of the Zengun Group and in conjunction with a bond issue. The construction group Zengun’s founders have, together with the other owners and senior officers, through Zengun Group AB (publ) (the “Company”) repurchased the shares in Zengun Group Holding AB from Segulah Fund V.

In connection with the acquisition, the Company has issued a secured bond in an amount of MSEK 450. The bond, with an interest amount of MSEK 600, is subject to a variable interest rate of STIBOR 3m + 8 per cent and has a final due date in May 2022. The Company has prepared a prospectus which has been approved by and registered at the Swedish Financial Supervisory Authority in accordance with the Swedish Trading in Financial Instruments Act (1991:980) and will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team primarily consisted of Magnus Pauli, Frida Bergqvist, Lina André, Gabriella Varga, Camilla Andersson, Anna Åhlberg, Josefine Lanker and Jolinn Uhlin.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024